2-D DIGE analysis of liver and red blood cells provides further evidence for oxidative stress in schizophrenia

Journal of Proteome Research

Volumn 6, Issue 1, 2007, Pages 141-149

  Prabakaran, Sudhakaran ^a   Wengenroth, Martina ^a   Lockstone, Helen E ^a   Lilley, Kathryn ^a   Leweke, F Markus ^b   Bahn, Sabine ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b UNIVERSITY OF COLOGNE   (Germany)

Author keywords

Oxidative stress; Peripheral disease markers; Proteomics; Schizophrenia

Indexed keywords

CLOZAPINE; NEUROLEPTIC AGENT; OLANZAPINE; PROTEOME;

ADULT; ARTICLE; CELL ASSAY; CLINICAL ARTICLE; CONTROLLED STUDY; ERYTHROCYTE; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; LIVER PARENCHYMA; MALE; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEOMICS; SCHIZOPHRENIA; TWO DIMENSIONAL GEL ELECTROPHORESIS;

ADULT; ANTIPSYCHOTIC AGENTS; ELECTROPHORESIS, GEL, TWO-DIMENSIONAL; ERYTHROCYTES; FEMALE; HEMOGLOBINS; HUMANS; ISOELECTRIC FOCUSING; LIVER; MALE; MIDDLE AGED; OXIDATIVE STRESS; PROTEOME; PROTEOMICS; SCHIZOPHRENIA;

EID: 33846609097     PISSN: 15353893     EISSN: None     Source Type: Journal    
DOI: 10.1021/pr060308a     Document Type: Article

References (41)

1. Jablensky, A.; Sartorius, N.; Ernberg, G.; Anker, M.; Korten, A.; Cooper, J. E.; Day, R.; Bertelsen, A. Schizophrenia: manifestations, incidence and course in different cultures. A World Health Organization ten-country study. Psychol. Med. Monogr. Suppl. 1992, 20, 1-97.
2. Shapiro, R. M. Regional neuropathology in schizophrenia: where are we? Where are we going? Schizophr. Res. 1993, 10 (3), 187-239.
3. Harrison, P. J. The neuropathology of schizophrenia. A critical review of the data and their interpretation. Brain 1999, 122 (Pt 4), 593-624.
4. Pearlson, G. D.; Marsh, L. Structural brain imaging in schizophrenia: a selective review. Biol. Psychiatry 1999, 46 (5), 627-649.
5. Harrison, P. J.; Roberts, G. W. The Neuropathology of Schizophrenia. Progress and Inerpretation; Oxford University Press: Oxforr, U.K., 2000.
6. Shenton, M. E.; Dickey, C. C.; Frumin, M.; McCarley, R. W. A review of MRI findings in schizophrenia. Schizophr. Res. 2001, 49 (1-2), 1-52.
7. Harrison, P. J.; Freemantle, N.; Geddes, J. R. Meta-analysis of brain weight in schizophrenia. Schizophr. Res. 2003, 64 (1), 25-34.
8. Liddle, P.; Pantelis, C. In Brain Imaging in Schizophrenia; Blackwell Science: Oxford, U.K., 2003; pp 403-417.
9. Lawrie, S. M.; Abukmeil, S. S. Brain abnormality in schizophrenia. A systematic and quantitative review of volumetric magnetic resonance imaging studies. Br. J. Psychiatry 1998, 172, 110-120.
10. Wright, I. C.; Rabe-Hesketh, S.; Woodruff, P. W.; David, A. S.; Murray, R. M.; Bullmore, E. T. Meta-analysis of regional brain volumes in schizophrenia. Am. J. Psychiatry 2000, 157 (1), 16-25.
11. Haupt, D. W.; Newcomer, J. W. Abnormalities in glucose regulation associated with mental illness and treatment. J. Psychosom. Res. 2002, 53 (4), 925-933.
12. Ryan, M. C.; Collins, P.; Thakore, J. H. Impaired fasting glucose tolerance in first-episode, drug-naive patients with schizophrenia. Am. J. Psychiatry 2003, 160 (2), 284-289.
13. Heiskanen, T.; Niskanen, L.; Lyytikainen, R.; Saarinen, P. I.; Hintikka, J. Metabolic syndrome in patients with schizophrenia. J. Clin. Psychiatry 2003, 64 (5), 575-579.
14. Torrey, E. F.; Yolken, R. H. The schizophrenia-rheumatoid arthritis connection: infectious, immune, or both? Brain, Behav., Immun. 2001, 15 (4), 401-410.
15. Flyckt, L.; Borg, J.; Borg, K.; Ansved, T.; Edman, G.; Bjerkenstedt, L.; Wiesel, F. A. Muscle biopsy, macro EMG, and clinical characteristics in patients with schizophrenia. Biol. Psychiatry 2000, 47 (11), 991-999.
16. Yao, J. K.; Thomas, E. A.; Reddy, R. D.; Keshavan, M. S. Association of plasma apolipoproteins D with RBC membrane arachidonic acid levels in schizophrenia. Schizophr. Res. 2005, 72 (2-3), 259-266.
17. Tsang, T. M.; Huang, J. T.; Holmes, E.; Bahn, S. Metabolic profiling of plasma from discordant schizophrenia twins: correlation between lipid signals and global functioning in female schizophrenia patients. J. Proteome Res. 2006, 5 (4), 756-760.
18. McGorry, P. D.; Mihalopoulos, C.; Henry, L.; Dakis, J.; Jackson. H. J.; Flaum, M.; Harrigan, S.; McKenzie, D.; Kulkarni, J.; Karoly, R. Spurious precision: procedural validity of diagnostic assessment in psychotic disorders. Am. J. Psychiatry 1995, 152 (2), 220-223.
19. Rosenhan, D. L. On being sane in insane places. Science 1973, 179 (70), 250-258.
20. Prabakaran, S.; Swatton, J. E.; Ryan, M. M.; Huffaker, S. J.; Huang, J. T.; Griffin, J. L.; Wayland, M.; Freeman, T.; Dudbridge, F.; Lilley, K. S.; Karp, N. A.; Hester, S.; Tkachev, D.; Mimmack, M. L.; Yolken, R. H.; Webster, M. J.; Torrey, E. F.; Bahn, S. Mitochondrial dysfunction in schizophrenia: evidence for compromised brain metabolism and oxidative stress. Mol. Psychiatry 2004, 9 (7), 684-697, 643.
21. Webster, K. A. Evolution of the coordinate regulation of glycolytic enzyme genes by hypoxia. J. Exp. Biol. 2003, 206 (Pt 17), 2911-2922.
22. Crawford, J. H.; Isbell, T. S.; Huang, Z.; Shiva, S.; Chacko, B. K.; Schechter, A. N.; Darley-Usmar, V. M.; Kerby, J. D.; Lang, J. D., Jr.; Kraus, D.; Ho, C.; Gladwin, M. T.; Patel, R. P. Hypoxia, red blood cells, and nitrite regulate NO-dependent hypoxic vasodilation. Blood 2006, 107 (2), 566-574.
23. Swatton, J. E.; Prabakaran, S.; Karp, N. A.; Lilley, K. S.; Bahn, S. Protein profiling of human postmortem brain using 2-dimensional fluorescence difference gel electrophoresis (2-D DIGE). Mol. Psychiatry 2004, 9 (2), 128-143.
24. Myung, J. K.; Lubec, G. Use of solution-IEF-fractionation leads to separation of 2673 mouse brain proteins including 255 hydrophobic structures. J. Proteome Res. 2006, 5 (5), 1267-1275.
25. Zuo, X.; Hembach, P.; Echan, L.; Speicher, D. W. Enhanced analysis of human breast cancer proteomes using micro-scale solution isoelectrofocusing combined with high resolution 1-D and 2-D gels. J. Chromatogr., B: Anal. Technol. Biomed. Life Sci. 2002, 782 (1-2), 253-265.
26. Zuo, X.; Speicher, D. W. Microscale solution isoelectrofocusing: a sample prefractionation method for comprehensive proteome analysis. Methods Mol. Biol. 2004, 244, 361-375.
27. 2 insult. Invest. Ophthalmol. Visual Sci. 2003, 44 (5), 2084-2093.
28. Ashburner, M.; Ball, C. A.; Blake, J. A.; Botstein, D.; Butler, H.; Cherry, J. M.; Davis, A. P.; Dolinski, K.; Dwight, S. S.; Eppig, J. T.; Harris, M. A.; Hill, D. P.; Issel-Tarver, L.; Kasarskis, A.; Lewis, S.; Matese, J. C.; Richardson, J. E.; Ringwald, M.; Rubin, G. M.; Sherlock, G. Gene ontology: tool for the unification of biology. The Gene Ontology Consortium. Nat. Genet. 2000, 25 (1), 25-29.
29. Maier, C. M.; Chan, P. H. Role of superoxide dismutases in oxidative damage and neurodegenerative disorders. Neurosdentist 2002, 8 (4), 323-334.
30. Ognjanovic, B.; Zikic, R. V.; Stajn, A.; Saicic, Z. S.; Kostic, M. M.; Petrovic, V. M. The effects of selenium on the antioxidant defense system in the liver of rats exposed to cadmium. Physiol. Res. 1995, 44 (5), 293-300.
31. Glatt, S. J.; Everall, I. P.; Kremen, W. S.; Corbeil, J.; Sasik, R.; Khanlou, N.; Han, M.; Liew, C. C.; Tsuang, M. T. Comparative gene expression analysis of blood and brain provides concurrent validation of SELENBP1 up-regulation in schizophrenia. Proc. Natl. Acad. Sci. U.S.A. 2005, 102 (43), 15533-15538.
32. Ponizovsky, A. M.; Barshtein, G.; Bergelson, L. D. Biochemical alterations of erythrocytes as an indicator of mental disorders: an overview. Harv. Rev. Psychiatry 2003, 11 (6), 317-332.
33. Vilkov, G. A.; Kiroi, R. I.; Stepnina, E. G.; Smimova, O. B.; Kovalenko, V. A.; Trapezontseva, R. A., [Lipid peroxidation and microviscosity of erythrocyte membranes in patients with schizophrenia]. Zh. Nevropatol. Psikhiatr. im. S. S. Korsakova 1991, 91 (10), 45-47.
34. Mahadik, S. P.; Mukherjee, S. Free radical pathology and antioxidant defense in schizophrenia: a review. Schizophr. Res. 1996, 19 (1), 1-17.
35. Peet, M.; Shah, S.; Selvam, K.; Ramchand, C. N. Polyunsaturated fatty acid levels in red cell membranes of unmedicated schizophrenic patients. World J. Biol. Psychiatry 2004, 5 (2), 92-99.
36. Weinberger, D. R.; Herman, K. F. Speculation on the meaning of cerebral metabolic hypofrontality in schizophrenia. Schizophr. Bull 1988, 14 (2), 157-168.
37. Williamson, P. Hypofrontality in schizophrenia: a review of the evidence. Can. J. Psychiatry 1987, 32 (5), 399-404.
38. Honey, G. D.; Fletcher, P. C.; Bullmore, E. T. Functional brain mapping of psychopathology. J. Neurol. Neurosurg. Psychiatry 2002, 72 (4), 432-439.
39. Andreasen, N. C.; O'Leary, D. S.; Flaum, M.; Nopoulos, P.; Watkins, G. L.; Boles Ponto, L. L.; Hichwa, R. D. Hypofrontality in schizophrenia: distributed dysfunctional circuits in neuroleptic-naive patients. Lancet 1997, 349 (9067), 1730-1734.
40. Barch, D. M.; Carter, C. S.; Braver, T. S.; Sabb, F. W.; MacDonald, A., III; Noll, D. C.; Cohen, J. D. Selective deficits in prefrontal cortex function in medication-naive patients with schizophrenia. Arch. Gen. Psychiatry 2001, 58 (3), 280-288.
41. Kim, J. J.; Mohamed, S.; Andreasen, N. C.; O'Leary, D. S.; Watkins, G. L.; Boles Ponto, L. L.; Hichwa, R. D. Regional neural dysfunctions in chronic schizophrenia studied with positron emission tomography. Am. J. Psychiatry 2000, 157 (4), 542-548.